Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK564280PMID: 33226743
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 8047-67-4
Drug Levels and Effects
Summary of Use during Lactation
Because sucroferric oxyhydroxide is not absorbed orally, it will not reach the bloodstream of the infant or cause any adverse effects in breastfed infants.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Aluminum Hydroxide, Calcium Acetate, Calcium Carbonate, Ferric Citrate, Sevelamer
Substance Identification
Substance Name
Sucroferric Oxyhydroxide
CAS Registry Number
8047-67-4
Drug Class
Breast Feeding
Lactation
Milk, Human
Ferric Compounds
Iron Compounds
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Review Iron Sucrose.[Drugs and Lactation Database (...]Review Iron Sucrose.. Drugs and Lactation Database (LactMed®). 2006
- Effect of Sucroferric Oxyhydroxide on Fibroblast Growth Factor 23 Levels in Hemodialysis Patients.[Nephron. 2018]Effect of Sucroferric Oxyhydroxide on Fibroblast Growth Factor 23 Levels in Hemodialysis Patients.Otsuki T, Utsunomiya K, Moriuchi M, Horikoshi S, Okamura M, Suzuki H, Okamura M, Maruyama N, Shibahara N, Abe M. Nephron. 2018; 140(3):161-168. Epub 2018 Jul 10.
- Review Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.[Curr Drug Metab. 2014]Review Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.Cozzolino M, Funk F, Rakov V, Phan O, Teitelbaum I. Curr Drug Metab. 2014; 15(10):953-65.
- Review Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.[Drugs. 2015]Review Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.Greig SL, Plosker GL. Drugs. 2015 Apr; 75(5):533-42.
- Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.[Nephrol Dial Transplant. 2015]Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM, et al. Nephrol Dial Transplant. 2015 Jun; 30(6):1037-46. Epub 2015 Feb 16.
- Sucroferric Oxyhydroxide - Drugs and Lactation Database (LactMed®)Sucroferric Oxyhydroxide - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...